HK Stock Market Move | HUTCHMED(00013) rose by more than 3% in the morning. The critical research data of fruquintinib will be announced at the ESMO Gastrointestinal Cancer Conference.

HUTCHMED (00013) rose over 3% in the morning, with a gain of 3.21% at the time of writing, at 16.72 Hong Kong dollars, with a transaction amount of 38.547 million Hong Kong dollars. On the news front, on June 25, HUTCHMED announced that the results of the pivotal phase II registration study of surufatinib (HMPL-453) for the treatment of patients with intrahepatic cholangiocarcinoma will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Tumours Congress in Munich, Germany, from July 1 to July 4, 2026. Based on the data from the study, the new drug application for surufatinib in the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma who have received prior systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement, was accepted by the China National Medical Products Administration in December 2025 and included in priority review.